Posted by Michael Wonder on 11 Dec 2023
CStone announces NMPA approval of sugemalimab as first-line treatment for oesophageal squamous cell carcinoma
8 December 2023 - This marks the 13th new drug application approval obtained by CStone and sugemalimab's fourth indication approved in China, following stage III and IV non-small-cell lung cancer and relapsed or refractory extranodal NK/T-cell lymphoma.
CStone Pharmaceuticals today announced that the National Medical Products Administration of China has approved the supplemental biologics license application for sugemalimab (Cejemly) in combination with fluorouracil and platinum-based chemotherapy as first-line treatment of unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
